Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status approved
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161; D04931
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 62991-2899; 69076-913; 15308-0712; 12780-0299; 0054-4581; 0378-3547
UNII E7WED276I5
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Productive cough22.02.03.005--
Psoriasis23.03.14.002; 10.02.01.0360.002810%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary granuloma22.01.01.0140.001041%Not Available
Pyrexia08.05.02.0030.018008%
Rash23.03.13.0010.011034%Not Available
Rash macular23.03.13.003--Not Available
Rectal cancer16.13.01.003; 07.21.05.002--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.0010.001561%
Renal failure20.01.03.005--Not Available
Rhinorrhoea22.12.03.021--
Sepsis11.01.11.003--
Shock24.06.02.0020.001041%Not Available
Skin cancer23.08.02.002; 16.03.02.0020.001561%Not Available
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.0030.001561%Not Available
Skin hyperpigmentation23.05.01.003--
Skin lesion23.03.03.0100.001041%Not Available
Small intestinal obstruction07.13.06.0010.002602%
Splenomegaly01.09.02.0010.001041%Not Available
Squamous cell carcinoma16.16.01.0020.001041%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.001041%Not Available
Stomatitis07.05.06.0050.004372%
Stress19.06.02.0040.002810%Not Available
Swelling08.01.03.015--Not Available
Swelling face08.01.03.100; 23.04.01.018; 10.01.05.018--Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
T-cell lymphoma11.05.17.006; 16.17.02.001; 01.11.02.0010.001561%Not Available
Therapeutic response unexpected08.06.01.0010.002290%Not Available
The 6th Page    First    Pre   6 7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene